alferminogene tadenovec
AXP000151.1 · Viral vector gene therapy
- Platform
- adenovirus (Ad5, non-replicating, FGF-4)
- Targets
- FGF4
- Originator
- Berlex / Schering AG
- Sponsor
- Angionetics (Gene Biotherapeutics)
Names
| Name | Type | Source |
|---|---|---|
| alferminogene tadenovec | preferred name, INN | curator, ncit |
| Generx | brand | press |
| Ad5FGF-4 | code | press |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- non-replicating Ad5 encoding human fibroblast growth factor 4
- Transgenes
- FGF4
- Route
- intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C184852
- FDA UNII
- 79EDH25YRK
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02928094 | Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia | Unknown | Phase 3 | 2023-01-01 | 2024-03-01 | 160 | Angina, Stable |
| NCT01550614 | Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease | Terminated | Phase 3 | 2012-03 | 2016-05 | 11 | Angina, Stable |
| NCT00438867 | Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization | Unknown | Phase 3 | 2007-05 | 2009-11 | 300 | Angina Pectoris |
| NCT00346437 | Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3) | Completed | Phase 2/3 | 2001-10 | 2005-01 | 416 | Angina Pectoris |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT00185263 | Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina | Unknown | Phase 2/3 | 2002-03 | 2005-01 | 116 | Stable Angina | name in title: Ad5FGF-4 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 23957658 | Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. | Expert opinion on biological therapy | 2013 | cited by trial NCT01550614 |
| PMID 17825712 | Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. | Journal of the American College of Cardiology | 2007 | cited by trial NCT00346437 |
| PMID 16218781 | Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. | Human gene therapy | 2005 | name in abstract: Ad5FGF-4 |
| PMID 14563572 | A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. | Journal of the American College of Cardiology | 2003 | name in title: Ad5FGF-4 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 18379964 | Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. | IDrugs : the investigational drugs journal | 2008 | name in title: alferminogene tadenovec |
| PMID 17722485 | Development of parallel line analysis criteria for recombinant adenovirus potency assay and definition of a unit of potency. | PDA journal of pharmaceutical science and technology | 2007 | name in abstract: Ad5FGF-4 |
| PMID 15958178 | A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene. | Analytical biochemistry | 2005 | name in abstract: Ad5FGF-4 |
| PMID 14988742 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2004 | name in abstract: Ad5FGF-4 |
| PMID 15180588 | Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease. | Current gene therapy | 2004 | name in abstract: Ad5FGF-4 |
| PMID 12894451 | Gene therapy for coronary artery disease: preclinical and initial clinical results with intracoronary administration of Ad5FGF-4. | Ernst Schering Research Foundation workshop | 2003 | name in title: Ad5FGF-4 |
| PMID 14615023 | Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. | The American journal of cardiology | 2003 | name in title: Ad5FGF-4 |
| PMID 11909005 | FGF-4 gene therapy GENERX--Collateral Therapeutics. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2002 | name in title: Generx |
| PMID 12031124 | A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. | Human gene therapy | 2002 | name in abstract: Ad5FGF-4 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R43NS061455 | Biomarker panel to differentiate stroke from stroke mimic | PREDICTION SCIENCES, LLC | MAN, ALBERT K | 2008–2008 | name in abstract: Generx |
| R44CA117001 | GeneRx - colorectal cancer recurrence prediction | PREDICTION SCIENCES, LLC | LINKE, STEVEN P | 2007–2008 | name in title: Generx |
| R43CA117001 | GeneRx - colorectal cancer recurrence prediction | PREDICTION SCIENCES, LLC | LINKE, STEVEN P | 2005–2005 | name in title: Generx |
| R44HL065791 | Improved Plasmid/Liposome Administration to the Lungs | GENERX+, INC. | SANDERS, JONATHAN R | 2002–2003 | name in abstract: Generx |
| R43MH066671 | Pharmacogenetic Prediction of Paroxetine Response | PREDICTION SCIENCES, LLC | HEROLD, CHRISTOPHER D | 2002–2002 | name in abstract: Generx |
| R41DK059732 | Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis | GENERX+, INC. | BRIGHAM, KENNETH L | 2001–2001 | name in abstract: Generx |
| R43HL065791 | IMPROVED PLASMID/LIPOSOME ADMINISTRATION TO THE LUNGS | GENERX+, INC. | SANDERS, JONATHAN R | 2000–2000 | name in abstract: Generx |
Notes
Generx: single intracoronary infusion of a non-replicating Ad5 carrying human FGF-4 to induce collateral vessel growth in refractory angina due to coronary artery disease. Reached phase 3 (AFFIRM / AWARE); FDA cleared a further US phase 3 study. Not a cancer product.
How to cite
alferminogene tadenovec (AXP000151.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000151.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.